Clinical Trials: A Study Coordinator on Recruitment and Pre-Screening

Summary

This video outlines the process of recruitment and pre-screening for clinical trials, from initial FDA approval to the screening visit. It highlights the role of study coordinators, the importance of patient outreach, and the detailed steps involved in informing potential participants about a trial.

Highlights

Trial Approval and Initial Awareness00:00:07

Clinical trials cannot recruit until approved by the FDA and a review board. Once approved, information is posted on platforms like clinicaltrials.gov and rare disease websites, leading to inquiries from patients, families, and clinicians. Patients must initiate contact with the study site.

First Contact with a Study Coordinator00:01:21

The first point of contact is usually a study coordinator, whose contact information is listed on clinicaltrials.gov. They provide more information about the trial, including the drug/treatment, and inclusion/exclusion criteria. Even if criteria seem not to fit, it's worth asking questions as some rules might have exceptions.

Initial Phone Call and Pre-screening00:02:42

The coordinator explains the study and commitment required, using a structured script to cover essential questions. This initial call is informational, acting as a pre-screen to gather general inclusion criteria and patient medical background. The next step involves reviewing medical records to assess potential eligibility.

Detailed Pre-screening and Consent Form Review00:04:30

Some institutions schedule a more detailed pre-screening call after reviewing medical records to ask specific questions about the patient's condition. Before a screening visit, the consent form is sent to the patient/family to review trial details, commitments, procedures, and potential invasiveness. This allows them to ask clarifying questions before committing to a screening visit.

The Screening Visit and Final Decision00:06:25

A screening visit is scheduled if the patient appears appropriate and meets initial criteria. This visit does not commit them to the trial; it's to determine eligibility. During this visit, the investigator meticulously reviews the consent form with the parent or patient, ensuring full understanding of the trial details, leading to an informed decision about participation.